Association of Cytidine Deaminase Polymorphism with Capecitabine Effectiveness in Breast Cancer Patients.

ABSTRACT:

Objective

Cancer is caused by abnormal growth and disruption of homeostatic mechanisms. Breast cancer is a major health problem and the second leading cause of death in women. Capecitabine is a prodrug of 5-fluorouracil, which is a non-cytotoxic agent and is used to treat advanced or metastatic breast cancer. Cytidine deaminase (CDA) plays an important role in the activation of capecitabine by acetylating 5-deoxycytidine in the liver, which ultimately leads to the formation of 5-fluorouracil. In this study, we aimed to investigate the relationship between cytidine deaminase polymorphism and capecitabine efficacy in breast cancer patients.

Methods

One hundred breast cancer patients aged 45 to 75 years were included in this study, all of whom received capecitabine as monothera

SUBMITTER: Aldeen Majeed AA 

PROVIDER: S-EPMC10909096 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature